News for Healthier Living

Experimental ADC Shows Promising Initial Activity in Head and Neck Cancers

The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase 1 trial presented by researchers at The University of Texas MD Anderson Cancer Center.

November 18, 2026


November 19 2026

November 18 2026

November 17 2026

November 16 2026

November 15 2026

November 13 2026

November 12 2026

November 11 2026

November 10 2026

November 9 2026

November 8 2026

November 7 2026

November 6 2026

November 5 2026